ABLBIO has a total of 11 patent applications. Its first patent ever was published in 2013. It filed its patents most often in United States, EPO (European Patent Office) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are OSE IMMUNOTHERAPEUTICS, XU KAI YUAN and VECT HORUS.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Australia | 2 | |
#4 | Russian Federation | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Moon Kyung Duk | 9 |
#2 | Lee Dong Heon | 5 |
#3 | Kang Kyung Jae | 5 |
#4 | Choi Yu Bin | 5 |
#5 | Kim Dong In | 5 |
#6 | Kim Young Min | 4 |
#7 | Song Dae Hae | 4 |
#8 | Eom Jae Hyun | 4 |
#9 | Jung Jin Won | 4 |
#10 | Kim Jae Yong | 4 |
Publication | Filing date | Title |
---|---|---|
US2016159929A1 | Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof |